LOS ANGELES, CA / ACCESSWIRE / November 27, 2018 / Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced that it will be presenting at the 11th annual LD Micro Main Event on Tuesday , December 5th at 9:30 AM PST /12:30 PM EST. CEO, Maurice Zauderer, Ph.D., will be presenting and meeting with investors.
The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.
View CHF Solutions' profile here: http://www.ldmicro.com/profile/VCNX
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
LifeSci Advisors, LLC
Phone: (646) 597-6979
JQA Partners, Inc.
Phone: (917) 885-7378
SOURCE: Vaccinex, Inc.